# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.
Kala Bio (NASDAQ:KALA) reported quarterly losses of $(3.16) per share which beat the analyst consensus estimate of $(4.40) by 2...
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $21 to ...
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(4.20) per share which missed the analyst consensus estimate o...
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $22 to ...
Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.